Access to medicines
We want to increase access to our medicines and vaccines to all patients, irrespective of where they live and their ability to pay.
Research practices
We recognise that biomedical research can raise ethical concerns and we aim to be open about our approach.
Ethical conduct
We are building on our strong culture in which all our decisions are guided by our values.
Environmental sustainability
We revised our environmental sustainability strategy in 2010, setting ambitious goals for GSK's impact across the entire value chain.
Our people
Our employment practices are designed to help us create the right workplace culture in which all GSK employees feel valued, respected, empowered and inspired.
Responsible business at GSK
We place great importance not just on what we achieve but on how we achieve it. We know that the research and development, manufacture and sale of our products can raise ethical issues, and we aim to be open about how we tackle them.
From our CEO
We are transforming GSK into a more competitive and efficient company. A company built on strong values and a deep commitment to excellence.
Download the 2010 CR Review and Report
Responsibility in action
-
Flexible pricing
Access to medicines
Pricing is one factor that impacts on access and we are pursuing a range of flexible pricing models in developing countries. -
Clinical research
Research practices
We are committed to public disclosure of all our clinical research, whether positive or negative for our medicines. -
Marketing
Ethical conduct
We market our products to healthcare professionals, hospitals and governments and recognise this raises some challenging issues. -
Climate change and energy
Environmental sustainability
Long-term goal for our entire value chain to be carbon neutral by 2050, with a 10% reduction in carbon footprint by 2015.